Trevena stock reports a USD 0.01 OTC quote near its yearly low

Published on 10/05/2026 at 15:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Trevena stock is tied to a central-nervous-system drug pipeline, including approved OLINVYK and investigational TRV734. Historical Q3 2024 revenue was USD 283,000.

TRVN, US89532E3071, Illustration mit AI erstellt.

Trevena stock (ISIN US89532E3071) was last quoted at USD 0.01 on OTC Markets on October 2, 2026, after the trading session data showed 210 shares changing hands. The quote sits between the 52-week low of USD 0.0003 and the 52-week high of USD 1.5005, leaving the stock close to the lower end of its annual trading range. Trevena's identifier and TRVN symbol are listed together in a securities list from Citibank.

OTC quote stays near yearly low

The market profile gives Trevena a market capitalization of USD 10,365 and classifies the company in healthcare biotechnology. The October 2 quote of USD 0.01 compares with the annual high of USD 1.5005, while the same session showed an opening price of USD 0.01 and a daily range of USD 0.01 to USD 0.01.

The price data also place the stock at USD 0.01 against a prior close of USD 0.01. That flat session result contrasts with the broad distance between the annual low of USD 0.0003 and the annual high of USD 1.5005, a spread that makes the share's trading history unusually wide in percentage terms.

Pipeline centers on CNS medicines

Trevena describes itself as a biopharmaceutical company focused on medicines for central nervous system disorders. Its portfolio includes OLINVYK, an FDA-approved injection for moderate-to-severe acute pain, as well as the investigational candidates TRV734 for opioid use disorder and TRV045 for conditions including diabetic neuropathic pain.

The investor page identifies the latest listed financial report as the quarter ended September 30, 2024. Yahoo Finance reports historical Q3 2024 revenue of USD 283,000 and GAAP earnings of negative USD 4.94 million. The same period's earnings per share was negative USD 5.79, compared with a negative USD 7.75 estimate.

Historical results frame the stock

The Q3 2024 figures show the scale of Trevena's operating base at that reporting point: revenue of USD 283,000 stood against a USD 4.94 million loss. Yahoo Finance also lists trailing revenue of USD 546,000 and trailing net income attributable to common shareholders of negative USD 34.04 million, figures labeled on the page as trailing measures rather than as a new quarterly report.

For investors, the central tension is visible in the numbers. Trevena retains an approved product and several development programs, while the historical revenue and earnings figures remain small relative to the losses reported for Q3 2024. The OTC quote of USD 0.01 on October 2, 2026, provides the latest dated market marker for that contrast.